Continuous enrichment of circulating tumor cells using a microfluidic lateral flow filtration chip

• Published in: Journal of Chromatography A 2015-01, Vol.1377, p.100-105
• Main Authors: Lee, Sung-Woo, Hyun, Kyung-A., Kim, Seung-Il, Kang, Ji-Yoon, Jung, Hyo-Il
• Format: Article
• Language: English
• Subjects: Cancer; Chips; Circulating; Circulating tumor cells(CTCs); Damage; Diagnosis; Enrichment; Filtration; Lateral flow filtration; Microfluidics; Tumors
• ISSN: 0021-9673
• DOI: 10.1016/j.chroma.2014.12.037

•We introduce microfluidic lateral flow filtration (μ-LaFF) chip designed for capturing CTCs.•The lateral flow conduces to the gentle cell capture and reduction of cell clogging.•We got a high capture efficiency (95%) and purity (99%), minimizing damage to CTCs.•μ-LaFF chip is expected to be useful in the diagnosis and prognosis of cancers. The isolation and characterization of circulating tumor cells (CTC) is of great importance in cancer diagnosis and prognosis. Highly sensitive detection of CTCs can be very difficult because they are extremely rare (i.e., 1-5 CTCs per 109 erythrocytes) in blood. Recently, various devices have been developed that exploit biochemical (affinity-based) and physical (size or density) methods. Antibody-based isolation has its own limitations, as the expression level of the epitopes for an antibody varies due to the heterogeneity of cancer cells. Harsh conditions associated with physical methods can cause the deformation and damage of CTCs during the isolation process. Here, we propose a microfluidic lateral flow filtration (μ-LaFF) chip in which lateral flow was combined with vertical flow into the filter to capture the CTCs gently. The CTCs experienced weak shear flow owing to the lateral flow and traveled alongside the filter channel until finally being captured. The vertical flow in the filter held the captured cells tightly and served as an exit for uncaptured hematological cells (white and red blood cells). From our μ-LaFF chip we obtained a high capture efficiency (95%) and purity (99%), minimizing any damage to the CTCs. Our μ-LaFF technology is expected to be useful in the diagnosis and prognosis of various cancers.